24 results on '"Schalm, Stefanie"'
Search Results
2. BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer.
3. Protein Kinase A Downregulation Delays the Development and Progression of Polycystic Kidney Disease
4. P464: PULSE DOSING OF POTENT AND SELECTIVE HETEROBIFUNCTIONAL MDM2 DEGRADER KT-253 DRIVES TUMOR REGRESSION AND DEMONSTRATES DIFFERENTIATED PHARMACOLOGY COMPARED TO P53/MDM2 SMALL MOLECULE INHIBITORS.
5. IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition
6. Development of KT-253, a Highly Potent and Selective Heterobifunctional MDM2 Degrader for the Treatment of Acute Myeloid Leukemia
7. Abstract 3934: KT-253, a highly potent and selective heterobifunctional MDM2 degrader for the treatment of wildtype p53 tumors with superior potency and differentiated biological activity compared to small molecule inhibitors (SMI)
8. Abstract 3328: Antitumor activity of BLU-945 and BLU-701 as single agents and in combination in EGFR L858R-driven models of NSCLC
9. Proteolytic processing of protocadherin proteins requires endocytosis
10. Phosphorylation of protocadherin proteins by the receptor tyrosine kinase Ret
11. Abstract 1467: BLU-945, a fourth-generation, potent and highly selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with intracranial activity, demonstrates robust in vivo antitumor activity in models of osimertinib-resistant non-small cell lung cancer (NSCLC)
12. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics
13. Abstract 954: The landscape of kinase fusions in cancer
14. Abstract 2296: IDH2 mutation induced histone and DNA hypermethylation is progressively reversed by small molecule inhibition
15. The landscape of kinase fusions in cancer
16. Molecular Mechanism of mTOR downstream signaling
17. Mutation Selective IDH Inhibitors Mediate Histone and DNA Methylation Changes
18. Abstract LB-164: IDH mutations and tumorgenicity
19. Characterization of a Conserved C-terminal Motif (RSPRR) in Ribosomal Protein S6 Kinase 1 Required for Its Mammalian Target of Rapamycin-dependent Regulation
20. TOS Motif-Mediated Raptor Binding Regulates 4E-BP1 Multisite Phosphorylation and Function
21. Identification of a Conserved Motif Required for mTOR Signaling
22. Regulation of Ribosomal S6 Kinase 2 by Effectors of the Phosphoinositide 3-Kinase Pathway
23. Ribosomal S6 Kinase 2 Inhibition by a Potent C-terminal Repressor Domain Is Relieved by Mitogen-activated Protein-Extracellular Signal-regulated Kinase Kinase-regulated Phosphorylation
24. Evaluation of Protein Kinase cAMP-Activated Catalytic Subunit Alpha as a Therapeutic Target for Fibrolamellar Carcinoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.